oxybutynin has been researched along with rivastigmine in 72 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.39) | 29.6817 |
| 2010's | 63 (87.50) | 24.3611 |
| 2020's | 8 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cho, KH; Choi, YH; Lee, DH; Lee, HM; Yun, SY | 1 |
| Farlow, MR; Gauthier, S; Grossberg, G; Meng, X; Olin, JT | 1 |
| Akehurst, R; Brandtmüller, A; Brennan, A; Nagy, B; Sullivan, SD; Thomas, SK | 1 |
| Grossberg, G; Meng, X; Olin, JT | 1 |
| Grossberg, GT; Meng, X; Olin, JT; Somogyi, M | 1 |
| Alva, G; Grossberg, GT; Meng, X; Olin, JT; Schmitt, FA | 1 |
| Choi, SH; Han, HJ; Kim, EJ; Lee, JH; Na, DL; Park, KW; Shim, YS | 1 |
| Adam, DN; Greenspoon, J; Herrmann, N | 1 |
| Articus, K; Baier, M; Kühn, F; Kurz, A; Preuss, UW; Tracik, F | 1 |
| Dhillon, S | 2 |
| Farlow, MR; Grossberg, GT; Meng, X; Olin, J; Somogyi, M | 1 |
| Chatani, Y; Fujii, A; Shinagawa, R; Shirahase, T; Suzuki, K; Toriyama, K | 1 |
| Arranz, FJ; Molinuevo, JL | 1 |
| Cytryn, E; Segers, K; Surquin, M | 1 |
| Hägg, S; Jönsson, AK; Lövborg, H | 1 |
| Bakchine, S; Bellelli, G; Black, SE; Caputo, A; Cummings, J; Downs, P; Froelich, L; Kressig, RW; Molinuevo, JL; Strohmaier, C | 1 |
| Pregelj, P | 1 |
| Cho, SJ; Choi, MS; Choi, SH; Han, HJ; Heo, JH; Kim, BC; Kim, KK; Lee, JY; Na, HR; Park, HY; Park, KW; Ryu, SH; Shin, JH; Yi, HA; Yoon, SJ | 1 |
| Aikawa, T; Arai, H; Ebihara, T; Furukawa, K; Kosaka, Y; Ohrui, T; Okinaga, S; Suzuki, M; Tomita, N; Une, K; Uwano, C | 1 |
| Adams, C; Haque, MS; Prasher, VP; Sachdeva, N | 1 |
| Fujii, M; Kajiwara, M; Kiyokawa, E; Sasaki, H; Satoh, S; Toukairin, Y | 1 |
| Dejthevaporn, C; Kulkantrakorn, K; Laptikultham, S; Pongpakdee, S; Rangseekajee, P; Rodprasert, K; Setthawatcharawanich, S; Tanyakitpisal, P; Thinkhamrop, B; Towanabut, S | 1 |
| Anand, KS; Dhikav, V | 1 |
| Hernández, B; Reñé, R; Ricart, J | 1 |
| Farlow, MR; Grossberg, GT; Meng, X; Sadowsky, CH; Somogyi, M | 1 |
| Bellelli, G; Cummings, J; Frölich, L; Grossberg, G; Krahnke, T; Molinuevo, JL; Strohmaier, C | 1 |
| Alva, G; Grossberg, G; Isaacson, R; Meng, X; Sadowsky, C; Somogyi, M | 1 |
| Adler, G; Articus, K; Mueller, B | 1 |
| Riepe, MW | 1 |
| Isik, AT; Soysal, P; Yay, A | 1 |
| Aguiar, P; Feres, A; Gomes, I; Melo, A; Monteiro, L | 1 |
| Frampton, JE | 1 |
| Amanatkar, HR; Grossberg, GT | 1 |
| Dautzenberg, PJ; Golüke, NM; Jessurun, N; Keijsers, CJ; van Strien, AM | 1 |
| Cho, SJ; Choi, SH; Han, HJ; Kim, JE; Kim, SG; Kwon, JC; Moon, SY; Park, JM; Park, KC; Park, KH; Park, KW; Seo, SW | 1 |
| Cagnin, A; Cester, A; Costa, B; Ermani, M; Gabelli, C; Gambina, G | 1 |
| Addante, F; Cascavilla, L; Ciccone, F; D'Onofrio, G; Elia, AC; Greco, A; Nuzzaci, C; Panza, F; Paris, F; Picoco, M; Pilotto, A; Sancarlo, D | 1 |
| Farlow, MR; Grossberg, GT; Meng, X; Velting, DM | 1 |
| Alva, G; Cummings, JL; Galvin, JE; Meng, X; Velting, DM | 1 |
| Balogh, R; Berkó, S; Budai-Szűcs, M; Csányi, E; Sinkó, B; Takács-Novák, K; Tóth, G; Vizserálek, G | 1 |
| Chaves, R; Knox, S; Mulick Cassidy, A; Müller, B; Osae-Larbi, J; Riepe, M; Weinman, J | 1 |
| Diaz, MCB; Rosales, RL | 1 |
| Ferris, S; Isaacson, RS; Meng, X; Velting, DM | 1 |
| Deardorff, WJ; Grossberg, GT; Nieto, RA | 1 |
| Callegari, F; He, L; Hong, Z; Shang, L; Strohmaier, C; Wang, N; Wang, YP; Weisskopf, M; Zhang, ZX; Zhao, G; Zhao, ZX | 1 |
| Lefèvre, G; Nozaki, S; Yamaguchi, M | 1 |
| Deardorff, WJ; Grossberg, GT | 1 |
| Amaro, MI; Cabral, LM; de Sousa, VP; Healy, AM; Simon, A | 2 |
| Castagna, A; Cotroneo, AM; Gareri, P; Ruotolo, G | 1 |
| Fujioka, S; Futagami, K; Kamimura, H; Ouma, S; Shibaguchi, H; Terasawa, M; Tsuboi, Y; Yasutaka, Y | 1 |
| Fujita, Y; Kamijo, Y; Kishino, T; Suzuki, Y; Usui, K; Yoshizawa, T | 1 |
| Cacciafesta, M; Ettorre, E; Servello, A | 1 |
| Choi, SH; Chung, EJ; Han, HJ; Kang, H; Kim, BC; Kim, EJ; Kim, KK; Kim, S; Ku, BD; Kwon, JC; Kwon, OD; Lee, HW; Lee, JH; Park, KH; Park, KW; Park, MY; Park, SW; Seo, SW; Shim, YS; Yang, DW; Yi, HA; Yoon, B | 1 |
| Naharci, MI; Tasci, I | 1 |
| Haque-Hussain, S; Khoo, ABS | 1 |
| Caltagirone, C; Colombo, D; Ori, A; Padovani, A; Simoni, L; Sorbi, S; Spalletta, G; Zagni, E | 1 |
| Abad-Santos, F; Álvarez, C; García-Arieta, A; González-Rojano, E; Gordon, J; Marcotegui, J; Morales-Alcelay, S | 1 |
| Bando, N; Hirano, T; Ishikawa, I; Matsumoto, Y; Mori, I; Mori, T; Nakamura, Y; Park, H; Tanaka, M; Tsuno, N | 1 |
| Chauhan, MK; Sharma, PK | 1 |
| Chen, SD; Guo, QH; Ji, Y; Jia, JP; Luo, BY; Ning, YP; Peng, DT; Wang, YP; Wei, WW; Xiao, J; Xiao, SF; Xiao, WZ; Xu, RL; Yang, YH; Yuan, Q; Zhang, JJ; Zhang, W | 1 |
| Navarro-Triviño, FJ; Ruiz-Villaverde, R | 1 |
| Duvvuri, K; Karan, R; Modali, S; Pathan, RK; Reinhardt, F; Scarmeas, N; Veldandi, UK | 1 |
| Larkin, HD | 1 |
| De la Torre, R; Iniesta, M; Koch, C; Morte, A; Schug, B; Schurad, B; Vaqué, A | 2 |
| Fujimoto, S; Imai, G; Matsuzono, K; Mita, Y | 1 |
| Fratta, KA; Ginder, M; Haggerty, DA | 1 |
9 review(s) available for oxybutynin and rivastigmine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.
Topics: Administration, Cutaneous; Alzheimer Disease; Cholinesterase Inhibitors; Dermatitis, Allergic Contact; Dermatitis, Contact; Humans; Medication Adherence; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2011 |
Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.
Topics: Administration, Cutaneous; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Medication Adherence; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2011 |
Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2011 |
[Pharmacological profile and clinical results of the rivastigmine patch as a new therapeutic agent for Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rats; Rivastigmine; Transdermal Patch | 2012 |
Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Neuroprotective Agents; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome | 2014 |
Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions.
Topics: Administration, Cutaneous; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine; Transdermal Patch; Treatment Outcome | 2014 |
Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Humans; Indans; Memantine; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Transdermal Patch | 2016 |
Sex-by-formulation interaction in bioequivalence trials with transdermal patches.
Topics: Analgesics, Opioid; Buprenorphine; Cholinesterase Inhibitors; Female; Fentanyl; Humans; Male; Rivastigmine; Sex Characteristics; Therapeutic Equivalency; Transdermal Patch | 2019 |
25 trial(s) available for oxybutynin and rivastigmine
| Article | Year |
|---|---|
The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Clinical Protocols; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Placebos; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome | 2010 |
Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models.
Topics: Alzheimer Disease; Brief Psychiatric Rating Scale; Cost-Benefit Analysis; Disease Progression; Female; Humans; Institutionalization; Male; Models, Economic; Neuroprotective Agents; Phenylcarbamates; Quality-Adjusted Life Years; Regression Analysis; Rivastigmine; Social Support; Transdermal Patch; United Kingdom | 2011 |
Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease.
Topics: Activities of Daily Living; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Capsules; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Prospective Studies; Rivastigmine; Time Factors; Transdermal Patch; Treatment Outcome | 2011 |
Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Retrospective Studies; Rivastigmine; Transdermal Patch; Treatment Outcome | 2011 |
Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Phenylcarbamates; Quality of Life; Retrospective Studies; Rivastigmine; Transdermal Patch | 2011 |
Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Male; Memantine; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome | 2011 |
A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Female; Humans; Male; Medication Adherence; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Transdermal Patch; Treatment Outcome | 2011 |
Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Retrospective Studies; Rivastigmine; Transdermal Patch | 2011 |
Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Phenylcarbamates; Rivastigmine; Transdermal Patch; Treatment Outcome | 2012 |
Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Apolipoproteins E; Cholinesterase Inhibitors; Drug Therapy, Combination; Female; Genotype; Humans; Male; Memantine; Middle Aged; Phenylcarbamates; Prospective Studies; Rivastigmine; Transdermal Patch | 2012 |
Rivastigmine patch and massage for Alzheimer's disease patients.
Topics: Activities of Daily Living; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Cognition; Female; Humans; Interpersonal Relations; Male; Massage; Mental Status Schedule; Phenylcarbamates; Rivastigmine; Tomography, X-Ray Computed; Transdermal Patch | 2013 |
Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index; Thailand; Transdermal Patch; Treatment Outcome | 2013 |
A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index; Transdermal Patch | 2013 |
Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Personal Autonomy; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome | 2013 |
Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Brief Psychiatric Rating Scale; Cholinesterase Inhibitors; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; Factor Analysis, Statistical; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Transdermal Patch | 2014 |
High-dose cholinergic therapy with rivastigmine patch does not prolong QTc time in patients with Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Electrophysiological Phenomena; Heart; Humans; Long QT Syndrome; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2014 |
Rivastigmine transdermal patch and physical exercises for Alzheimer's disease: a randomized clinical trial.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Caregivers; Cognition; Exercise Therapy; Female; Humans; Male; Neuroprotective Agents; Phenylcarbamates; Psychiatric Status Rating Scales; Quality of Life; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome | 2014 |
Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.
Topics: Aged; Alleles; Alzheimer Disease; Apolipoprotein E4; Butyrylcholinesterase; Female; Genetic Testing; Genotype; Humans; Male; Memantine; Middle Aged; Neuroprotective Agents; Odds Ratio; Rivastigmine; Transdermal Patch | 2015 |
A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Follow-Up Studies; Geriatric Assessment; Humans; Male; Middle Aged; Neuroprotective Agents; Pilot Projects; Psychiatric Status Rating Scales; Risk Factors; Rivastigmine; Transdermal Patch | 2015 |
Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Case-Control Studies; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Memantine; Neuroprotective Agents; Phenylcarbamates; Psychiatric Status Rating Scales; Quality of Life; Rivastigmine; Transdermal Patch; Treatment Outcome | 2015 |
Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Rivastigmine; Severity of Illness Index; Transdermal Patch | 2016 |
Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Asian People; Cognition Disorders; Double-Blind Method; Drug Administration Routes; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Mental Status Schedule; Middle Aged; Neuroprotective Agents; Retrospective Studies; Rivastigmine; Statistics, Nonparametric; Transdermal Patch; Treatment Outcome | 2016 |
Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Republic of Korea; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome; White Matter | 2017 |
Bioavailability Study of a Transdermal Patch Formulation of Rivastigmine Compared with Exelon in Healthy Subjects.
Topics: Administration, Cutaneous; Adult; Biological Availability; Cross-Over Studies; Healthy Volunteers; Humans; Rivastigmine; Transdermal Patch | 2022 |
Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon® Transdermal Patch (Daily)- A Randomized Clinical Trial.
Topics: Adult; Alzheimer Disease; Biological Availability; Cholinesterase Inhibitors; Humans; Male; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2022 |
38 other study(ies) available for oxybutynin and rivastigmine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
A case of rivastigmine toxicity caused by transdermal patch.
Topics: Aged; Female; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2011 |
Rivastigmine patches: fatal overdoses.
Topics: Alzheimer Disease; Drug Overdose; Humans; Medication Errors; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2011 |
Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Female; Humans; Male; Medication Adherence; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2012 |
Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Belgium; Cholinesterase Inhibitors; Delirium; Drug Eruptions; Female; Hospitals, University; Humans; Incidence; Male; Medical Records; Middle Aged; Nootropic Agents; Outpatient Clinics, Hospital; Phenylcarbamates; Pilot Projects; Retrospective Studies; Rivastigmine; Sweating; Transdermal Patch; Weather | 2012 |
A fatal outcome after unintentional overdosing of rivastigmine patches.
Topics: Aged, 80 and over; Cholinesterase Inhibitors; Dementia; Drug Labeling; Drug Overdose; Fatal Outcome; Humans; Male; Medication Errors; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2012 |
Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dermatitis, Contact; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Neuropsychological Tests; Patient Compliance; Phenylcarbamates; Prospective Studies; Rivastigmine; Transdermal Patch; Treatment Outcome; Vomiting | 2012 |
Rivastigmine dermal patch solves eating problems in an individual with advanced Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Deglutition Disorders; Female; Humans; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Transdermal Patch | 2012 |
Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome-pilot study.
Topics: Alzheimer Disease; Analysis of Variance; Delayed-Action Preparations; Down Syndrome; Female; Humans; Male; Medication Adherence; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Pilot Projects; Rivastigmine; Transdermal Patch | 2013 |
Acute dystonic reaction with rivastigmine.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Diazepam; Dose-Response Relationship, Drug; Dystonic Disorders; Female; Humans; Magnetic Resonance Imaging; Muscle Relaxants, Central; Phenylcarbamates; Rivastigmine; Transdermal Patch; Treatment Outcome | 2013 |
From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Patient Satisfaction; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2014 |
The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions.
Topics: Aged; Alzheimer Disease; Caregivers; Cost of Illness; Female; Humans; Male; Medication Adherence; Neuroprotective Agents; Prospective Studies; Rivastigmine; Surveys and Questionnaires; Transdermal Patch | 2014 |
Which rivastigmine formula is better for heart in elderly patients with Alzheimer's disease: oral or patch?
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Arrhythmias, Cardiac; Cholinesterase Inhibitors; Electrocardiography; Female; Humans; Hypotension; Male; Phenylcarbamates; Retrospective Studies; Rivastigmine; Transdermal Patch | 2014 |
Skin lesions after oral acetylcholinesterase inhibitor therapy: a case report.
Topics: Administration, Oral; Aged; Cholinesterase Inhibitors; Drug Eruptions; Galantamine; Humans; Male; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2014 |
Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Humans; Male; Neuropsychological Tests; Rivastigmine; Transdermal Patch; Treatment Outcome | 2015 |
Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease.
Topics: Administration, Cutaneous; Aged; Alzheimer Disease; Dose-Response Relationship, Drug; Drug Eruptions; Female; Humans; Incidence; Male; Neuroprotective Agents; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index; Transdermal Patch | 2015 |
Permeability test for transdermal and local therapeutic patches using Skin PAMPA method.
Topics: Administration, Cutaneous; Chemistry, Pharmaceutical; Fentanyl; Humans; In Vitro Techniques; Ketoprofen; Kinetics; Membranes, Artificial; Models, Biological; Nicotine; Permeability; Rivastigmine; Skin; Skin Absorption; Solubility; Technology, Pharmaceutical; Transdermal Patch | 2015 |
Factors Associated with Greater Adherence to and Satisfaction with Transdermal Rivastigmine in Patients with Alzheimer's Disease and Their Caregivers.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Female; Humans; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Rivastigmine; Surveys and Questionnaires; Transdermal Patch | 2015 |
A Case Report on Dyskinesia Following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's Disease: Perspective in the Movement Disorders Spectrum Following Use of Cholinesterase Inhibitors.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dyskinesias; Electroencephalography; Female; Humans; Neuroimaging; Phenylcarbamates; Rivastigmine; Transdermal Patch; Treatment Outcome; Withholding Treatment | 2015 |
Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Humans; Nausea; Rivastigmine; Transdermal Patch; Vomiting | 2016 |
Pharmacokinetic Modeling to Simulate the Concentration-Time Profiles After Dermal Application of Rivastigmine Patch.
Topics: Administration, Cutaneous; Administration, Intravenous; Biological Availability; Cholinesterase Inhibitors; Computer Simulation; Models, Theoretical; Rivastigmine; Skin Absorption; Tissue Distribution; Transdermal Patch | 2016 |
Comparative evaluation of rivastigmine permeation from a transdermal system in the Franz cell using synthetic membranes and pig ear skin with in vivo-in vitro correlation.
Topics: Administration, Cutaneous; Animals; Ear, External; In Vitro Techniques; Membranes, Artificial; Permeability; Rivastigmine; Skin; Skin Absorption; Swine; Transdermal Patch | 2016 |
The CITIRIVAD Study: CITIcoline plus RIVAstigmine in Elderly Patients Affected with Dementia Study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Cognition; Cytidine Diphosphate Choline; Female; Humans; Male; Neuropsychological Tests; Retrospective Studies; Rivastigmine; Transdermal Patch | 2016 |
Influence of Memantine on Continuous Treatment with Rivastigmine Patches-Retrospective Study Using the Logistic Regression Analysis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Memantine; Middle Aged; Patient Compliance; Retrospective Studies; Rivastigmine; Transdermal Patch | 2017 |
Development of a Discriminative In Vitro Release Test for Rivastigmine Transdermal Patches Using Pharmacopeial Apparatuses: USP 5 and USP 6.
Topics: Drug Liberation; Pharmacopoeias as Topic; Rivastigmine; Solubility; Transdermal Patch | 2017 |
Acute cholinergic syndrome in a patient with mild Alzheimer's type dementia who had applied a large number of rivastigmine transdermal patches on her body.
Topics: Administration, Cutaneous; Aged, 80 and over; Alzheimer Disease; Blood Pressure; Cholinesterase Inhibitors; Drug Overdose; Female; Heart Rate; Humans; Hypertension; Neurotoxicity Syndromes; Rivastigmine; Severity of Illness Index; Tachycardia, Sinus; Transdermal Patch | 2017 |
Improvement in behavioral and psychological symptoms of dementia by rivastigmine patch in a group of Italian elderly patients with Alzheimer's disease.
Topics: Acetylcholinesterase; Administration, Cutaneous; Aged; Alzheimer Disease; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognition; Female; GPI-Linked Proteins; Humans; Italy; Male; Mental Health; Mental Status and Dementia Tests; Retrospective Studies; Rivastigmine; Time Factors; Transdermal Patch; Treatment Outcome | 2017 |
Angioedema Caused by Rivastigmine Patch: A Rare Case.
Topics: Aged, 80 and over; Angioedema; Cholinesterase Inhibitors; Female; Humans; Rare Diseases; Rivastigmine; Transdermal Patch | 2018 |
A differential diagnosis for annular lesions: contact dermatitis to transdermal rivastigmine patches.
Topics: Aged; Dermatitis, Contact; Diagnosis, Differential; Humans; Male; Memory Disorders; Neuroprotective Agents; Rivastigmine; Transdermal Patch | 2018 |
Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A Post Hoc Analysis of the EVOLUTION Study.
Topics: Administration, Oral; Aged; Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Cognition; Drug Substitution; Female; Humans; Italy; Male; Mental Competency; Mental Status and Dementia Tests; Psychological Techniques; Rivastigmine; Sex Factors; Transdermal Patch; Treatment Outcome | 2018 |
Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study.
Topics: Aged, 80 and over; Alzheimer Disease; Appetite; Attitude to Health; Body Weight; Cholinesterase Inhibitors; Cognitive Dysfunction; Eating; Female; Humans; Male; Mental Status and Dementia Tests; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome | 2019 |
Optimization and characterization of rivastigmine nanolipid carrier loaded transdermal patches for the treatment of dementia.
Topics: Administration, Cutaneous; Animals; Blood Specimen Collection; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Dementia; Drug Liberation; Humans; Lipids; Liposomes; Nanocapsules; Neuroprotective Agents; Rats, Wistar; Rivastigmine; Transdermal Patch | 2019 |
[Several issues analysis on the treatment of Alzheimer's disease with rivastigmine transdermal patch].
Topics: Alzheimer Disease; Humans; Rivastigmine; Transdermal Patch; Treatment Outcome | 2020 |
Allergic contact dermatitis caused by 2-ethylhexyl acrylate in a rivastigmine transdermal therapeutic system.
Topics: Acrylates; Adhesives; Aged, 80 and over; Cholinesterase Inhibitors; Dermatitis, Allergic Contact; Humans; Male; Rivastigmine; Transdermal Patch | 2020 |
Real-world Utilisation of the Rivastigmine Transdermal Patches Accompanying the Use of Risk Minimisation Tools in Patients with Dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Humans; Male; Medication Adherence; Neuroprotective Agents; Patient Education as Topic; Rivastigmine; Transdermal Patch | 2021 |
First Donepezil Transdermal Patch Approved for Alzheimer Disease.
Topics: Administration, Cutaneous; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Nootropic Agents; Rivastigmine; Transdermal Patch | 2022 |
Improper Application of a Rivastigmine Patch to the Back of the Neck Induced Toxic Symptoms.
Topics: Aged, 80 and over; Alzheimer Disease; Female; Humans; Rivastigmine; Transdermal Patch | 2023 |
Oral and Transdermal Rivastigmine for the Treatment of Anticholinergic Delirium: A Case Report.
Topics: Acetylcholinesterase; Anticholinergic Syndrome; Antidotes; Cholinergic Antagonists; Cholinesterase Inhibitors; Delirium; Female; Humans; Middle Aged; Physostigmine; Rivastigmine; Transdermal Patch | 2023 |